FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

A panel of outside experts advising the US FDA backed the safety of Grail's NASDAQ:GRAL blood-based cancer detection test, Galleri, on Wednesday, though members were divided on the evidence supporting its effectiveness.While all the 10 panel members backed Galleri's safety, support for its effectiv…